Enhance Health, a healthcare platform delivering at-home monitoring and care workflows for liver disease, chronic kidney disease, and urea cycle disorders, announced today the appointment of Dave Firdaus to its Strategic Advisory Board.
Dave is a highly accomplished healthcare CEO, board leader, and growth strategist with a proven track record of advancing care for high-need and chronic patient populations across the United States. His extensive expertise in insurtech, healthcare growth strategy, and go-to-market scaling will be instrumental as Enhance Health expands its proactive health monitoring platform for liver disease, urea cycle disorders, and other high-burden chronic conditions.
"We are thrilled to welcome Dave to our advisory board," said Enhance Health CEO Matt Leming, PhD. "His deep experience scaling healthcare ventures, navigating complex healthcare ecosystems, and driving commercial growth aligns seamlessly with our mission to transform episodic, reactive care into continuous, proactive management for chronic disease patients."
Firdaus brings decades of strategic and operational leadership to Enhance Health. He previously served as Board Chairman of Gold Kidney Health Plan, as well as Board Chairman of Clever Care Health Plan, an insurtech company dedicated to delivering culturally sensitive healthcare to underserved communities. Throughout his career, Firdaus has successfully raised over $160 million in equity funding to advance innovative care models for vulnerable and chronic patient populations.
"Enhance Health is addressing a critical unmet need in chronic disease management by bringing continuous monitoring directly into the home," said Dave. "I look forward to working alongside the team to help advance the platform's mission and deliver meaningful, long-term health outcomes for patients who need them most."
About Enhance Health
Enhance Health is a healthcare platform delivering at-home monitoring and care workflows for liver disease, chronic kidney disease, and urea cycle disorders. By combining proprietary monitoring technology with AI analytics and continuous data capture, Enhance Health aims to improve patient outcomes and reduce the burden on traditional healthcare systems through proactive, data-driven care. The company's Breeze device has received Breakthrough Device Designation from the FDA. To learn more, visit enhancehealthinc.com
About VIC Tech
Enhance Health is part of the portfolio of VIC Tech, a venture studio focused on creating companies from innovative academic research. Enhance's Breeze is the third device from a VIC Tech portfolio company to receive Breakthrough Device Designation from the FDA, highlighting VIC’s consistent track record of advancing impactful health technologies toward clinical and commercial success.